Acceleron’s research focuses on engaging the biology of the transforming growth factor beta (TGF-beta) superfamily, a large group of proteins that are key regulators in the growth and repair of tissues throughout the human body.

Our strategy is to develop therapies that selectively target multiple ligands (proteins) in the TGF-beta superfamily, which play critical roles in the development of serious diseases. Our deep scientific expertise and leadership in this target-rich area of biology have enabled us to build and continue to expand a pipeline of innovative products with profound effects on the production of red blood cells, growth of skeletal muscle, restoration of the pulmonary vasculature, and other areas for potential future drug development.

The size and diversity of the TGF-beta protein superfamily—made up of 30 ligands, 12 receptors and 10 ligand traps—and the power of our research platform, hold the keys to many more discoveries with life-altering therapeutic potential.